A number of vascular therapies could benefit from advanced methods for presentation of
angiogenic growth factors, including growth of endothelium on small caliber vascular grafts …

Although vascular endothelial growth factor (VEGF) has been described as a potent
angiogenic stimulus, its application in therapy remains difficult: blood vessels formed by …

Clinical trials of therapeutic angiogenesis by vascular endothelial growth factor (VEGF) gene
delivery failed to show efficacy. Major challenges include the need to precisely control in …

Vascular endothelial growth factor (VEGF) is a key factor in endothelial cell biology and
blood vessel formation and a candidate therapeutic for the stimulation of angiogenesis …

A major challenge for therapeutic delivery of angiogenic agents such as vascular
endothelial growth factor (VEGF) is to achieve sustained, low dose signaling leading to …

Synergy in the downstream signaling pathways of the vascular endothelial growth factor
receptor-2 (VEGFR-2) and the integrin αvβ3 is critical for blood vessel formation. Thus …

Two soluble forms of vascular endothelial growth factor (VEGF) receptors, sVEGFR‐1 and
sVEGFR‐2, are physiologically released and overproduced in some pathologies. They are …

2. Background Vascular disease affects a large segment of the human population, and is the
leading cause of death in the United States. Each year in the US 800,000 individuals survive …

Vascular endothelial growth factor (VEGF) has been extensively investigated to promote
vascularization at damaged or diseased sites and in tissue implants. Here we are interested …

Local, controlled induction of angiogenesis remains a challenge that limits tissue
engineering approaches to replace or restore diseased tissues. We present a new class of …